Departamento de Química, Facultad de Farmacia, Universidad San Pablo CEU, Urbanización Montepríncipe, 28668, Boadilla del Monte, Madrid, Spain.
Org Biomol Chem. 2011 Jun 21;9(12):4587-99. doi: 10.1039/c0ob00852d. Epub 2011 May 6.
A new series of MMP2 inhibitors is described, following a fragment-based drug design approach. One fragment containing an azide group and a well known hydroxamate Zinc Binding Group in a α-sulfone, α-tetrahydropyrane scaffold, has been synthesized. Water-LOGSY, STD and competition-STD experiments indicate that this fragment binds to the active site of the enzyme. A click chemistry reaction was used to connect the azide to lipophilic alkynes selected to interact selectively with the S1' subunit of MMP2, as shown by docking and molecular dynamic experiments of the designed compounds. The most potent compounds 18 and 19 displayed an IC(50) of 1.4 and 0.3 nM against MMP2 respectively, and showed negligible activity towards MMP1 and MMP7, two metalloproteinases which have a shallow S1' subsite. Compound 18 also showed a promising selectivity profile against some antitarget metalloproteinases, such as MMP8, and considerably less activity against MMP14 (IC(50) = 65 nM), and MMP9 (IC(50) = 98 nM), other MMPs characterized by having a deep S1' pocket and, therefore, more similar to MMP2.
一种新的 MMP2 抑制剂系列被描述出来,该抑制剂采用了基于片段的药物设计方法。一个片段包含一个叠氮基团和一个众所周知的锌结合基团,位于 α-砜基、α-四氢呋喃骨架中,已被合成。水LOGSY、STD 和竞争 STD 实验表明该片段与酶的活性部位结合。点击化学反应用于将叠氮化物连接到疏水性炔烃上,这些炔烃是根据对接和设计化合物的分子动力学实验,选择性地与 MMP2 的 S1'亚基相互作用。最有效的化合物 18 和 19 对 MMP2 的 IC50 分别为 1.4 和 0.3 nM,对 MMP1 和 MMP7(两种金属蛋白酶,其 S1'亚基较浅)几乎没有活性。化合物 18 对一些抗靶标金属蛋白酶(如 MMP8)也表现出有前景的选择性特征,对 MMP14(IC50=65 nM)和 MMP9(IC50=98 nM)的活性则明显降低,这两种 MMPs 的 S1'口袋较深,因此与 MMP2 更为相似。